MFCD00126723 manufacturers
- KM02894
-
- $29.00
-
2026-05-06
- CAS:116850-74-9
- Purity: 99.98%
- Supply Ability: 10g
|
| | MFCD00126723 Basic information |
| Product Name: | MFCD00126723 | | Synonyms: | MFCD00126723;N1-methyl-2-(2-thienylcarbonyl)hydrazine-1-carbothioamide;N-methyl-2-(2-thienylcarbonyl)hydrazinecarbothioamide;N-methyl-2-(thiophen-2-ylcarbonyl)hydrazinecarbothioamide;2-Thiophenecarboxylic acid, 2-[(methylamino)thioxomethyl]hydrazide;KM02894;N-Methyl-2-(thiophene-2-carbonyl)hydrazinecarbothioamide | | CAS: | 116850-74-9 | | MF: | C7H9N3OS2 | | MW: | 215.3 | | EINECS: | | | Product Categories: | | | Mol File: | 116850-74-9.mol |  |
| | MFCD00126723 Chemical Properties |
| density | 1.359±0.06 g/cm3(Predicted) | | pka | 10.19±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | MFCD00126723 Usage And Synthesis |
| Uses | KM02894 is an inhibitor of glutamate release. Cancer cells release high levels of glutamate, which disrupts normal bone turnover and may lead to cancer-induced bone pain. KM02894 can be used for cancer related research[1]. | | References | [1] Fazzari J, et.al. Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain. Sci Rep. 2015 Feb 11;5:8380. DOI:10.1038/srep08380 |
| | MFCD00126723 Preparation Products And Raw materials |
|